看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。+ U% {# m1 I1 ^/ ^% v& i7 \
% O4 q/ c/ U, H/ O" l6 j0 X% N2 n q+ v$ }
Currently available feasibility data for possible combination strategies. # u& [6 |, D; T) [
————————————————————————————————
! H' O. Y$ }8 q3 n" m5 h3 p: T# w- }, mCombination Feasibility according to preliminary data
. \# i: C# d1 L—————————————————————————————————— q/ C# ^! y/ h. b1 H
Bevacizumab + sorafenib Yes, reduced dose
% p% l3 ? U' V( R; U6 \4 NBevacizumab + sunitinib† No
, ^3 U8 F- {: O) {: {Bevacizumab + temsirolimus Yes
" i0 ]2 G8 ], |3 mBevacizumab + everolimus Yes 9 B7 {' R- o, J7 j, b
Sorafenib + sunitinib ?
9 W v; y/ s! ]% F& h p, ~Sorafenib + temsirolimus Yes, reduced dose
% d E x5 m% V) }# W2 V! | kSorafenib + everolimus Yes, reduced dose : T `4 W% U. {
Sunitinib + temsirolimus† No
# J; ?& G! e! i9 ~5 tSunitinib + everolimus ?
2 }! k- U8 }4 ~Temsirolimus + everolimus ?
5 q+ f; l- h) _& H- p————————————————————
# N) W0 ^. j& ?†Led to US FDA warning.
+ T0 M2 U1 s( x" s; }) P" ^% {?: As yet unattempted combination.
: J$ o4 L5 u- a5 s4 k: Z$ i |
显身卡
